Trial Profile
Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma With Cutaneous Presentation: A Biomarker Phase Ib/IIa Study
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Acimtamig (Primary)
- Indications Anaplastic large cell lymphoma; Cutaneous T-cell lymphoma; Lymphoma; Mycosis fungoides
- Focus Biomarker; Pharmacodynamics
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 07 Dec 2020 Results presented in the Affimed Therapeutics Media Release.
- 04 Nov 2020 Results presented in an Affimed Media Release.